News
DCTH
11.72
-0.38%
-0.05
Weekly Report: what happened at DCTH last week (0601-0605)?
Weekly Report · 5d ago
Weekly Report: what happened at DCTH last week (0525-0529)?
Weekly Report · 06/01 09:16
Delcath Systems announces ASCO 2026 investigator initiated trials-in-progress
TipRanks · 05/26 20:05
Delcath Systems flags Phase 2 study sequencing HEPZATO liver perfusion with tebentafusp in metastatic uveal melanoma
PUBT · 05/26 20:01
H.C. Wainwright Sticks to Its Buy Rating for Delcath Systems (DCTH)
TipRanks · 05/26 17:52
Weekly Report: what happened at DCTH last week (0518-0522)?
Weekly Report · 05/25 09:17
Weekly Report: what happened at DCTH last week (0511-0515)?
Weekly Report · 05/18 09:17
Delcath Systems grants 24,500 RSUs under 2023 inducement plan
PUBT · 05/15 20:01
DELCATH SYSTEMS, INC. ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 05/15 20:01
Delcath Shareholders Approve Expanded Equity Plan and Governance
TipRanks · 05/14 12:50
Delcath Systems shareholders approved 1,800,000-share increase to omnibus equity plan
PUBT · 05/14 12:24
Delcath Systems management attends H.C. Wainwright BioConnect Investor Conference
PUBT · 05/12 12:01
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Barchart · 05/12 07:00
Weekly Report: what happened at DCTH last week (0504-0508)?
Weekly Report · 05/11 09:16
Delcath Systems Balances Growth with Rising Costs
TipRanks · 05/09 01:25
H.C. Wainwright Reaffirms Their Buy Rating on Delcath Systems (DCTH)
TipRanks · 05/08 10:37
Delcath outlines at least $100M 2026 revenue as it targets 37 active centers by year-end
Seeking Alpha · 05/08 03:32
Delcath Systems presents new data on M-PHP at ESMO
TipRanks · 05/07 14:11
Delcath Systems reports Q1 EPS (3c), consensus (9c)
TipRanks · 05/07 13:35
Delcath Systems FY2026 Revenue expected to be more than $100.000M vs $104.070M Est
Benzinga · 05/07 12:47
More
Webull provides a variety of real-time DCTH stock news. You can receive the latest news about Delcath Sys through multiple platforms. This information may help you make smarter investment decisions.
About DCTH
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).